Alx oncology presents positive updated data from aspen-06 phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with her2-positive gastric cancer

South san francisco, calif., jan. 23, 2025 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or the “company”) (nasdaq: alxo), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, announced positive updated data from the aspen-06 phase 2 clinical trial demonstrating that the company's investigational cd47-blocker evorpacept generates a durable clinical response with a well-tolerated safety profile among patients with previously treated her2-positive advanced gastric cancer (gc) or gastroesophageal junction (gej) cancer. the updated results, which build upon previously announced topline results, will be shared today in an oral presentation (abstract #332) at the 2025 american society of clinical oncology (asco) gastrointestinal cancers symposium in san francisco.
ALXO Ratings Summary
ALXO Quant Ranking